We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Antihypertensive and biochemical effects of indacrinone enantiomers.
The enantiomers of indacrinone ( I ) , an investigational loop diuretic , have different pharmacologic activity . The ( - ) enantiomer is natriuretic , and the ( + ) enantiomer is uricosuric . To determine the antihypertensive effects and an isouricemic ratio of indacrinone enantiomers , 37 patients with sitting diastolic blood pressure ( BP ) between 90 and 104 mm Hg , after a 4-week placebo washout , r and omly received one of the ratios of I enantiomers , namely -2.5/+80 mg ( A ) , -5/+80 mg ( B ) , -10/+80 mg ( C ) or placebo ( P ) , once daily for 12 weeks in a double-blind , parallel study . The mean reductions ( baseline-end of treatment ) in BP of 23/8 , 20/10 and 25/10 mm Hg with treatments A , B and C respectively were greater ( p less than 0.01 ) than that on P ( 0/3 ) . Initially , serum uric acid decreased with treatments A and B but not with C. Mean changes in serum uric acid were -0.3 , -0.4 , 0.2 and 0.3 mg/dl respectively with treatments A , B , C and P. The ratio of -10/+80 mg produced least variation in serum uric acid . Reduction in serum K+ and Cl- appeared to be dose related to ( - ) enantiomer . No serious adverse effects were reported . A 1:9 ratio of I enantiomers intended for wide-scale use as a diuretic also showed good antihypertensive activity , a favorable uric acid profile and absence of hepatic toxicity in 14 patients
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .